Request Demo
Recent blog posts
Latest Hotspot
8 min read
Primary carnitine deficiency Indication Strategy Report 2026: SLC22A5, Trials and Deals
23 July 2026
2026 Primary carnitine deficiency strategy: epidemiology, SLC22A5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Carnitine palmitoyltransferase II deficiency Indication Strategy Report 2026: CPT2, Trials and Deals
23 July 2026
2026 Carnitine palmitoyltransferase II deficiency strategy: epidemiology, CPT2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: HADHA, Trials and Deals
23 July 2026
2026 Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency strategy: epidemiology, HADHA biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Very long-chain acyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: ACADVL, Trials and Deals
23 July 2026
2026 Very long-chain acyl-CoA dehydrogenase deficiency strategy: epidemiology, ACADVL biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Medium-chain acyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: ACADM, Trials and Deals
23 July 2026
2026 Medium-chain acyl-CoA dehydrogenase deficiency strategy: epidemiology, ACADM biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Isovaleric acidemia Indication Strategy Report 2026: IVD, Trials and Deals
23 July 2026
2026 Isovaleric acidemia strategy: epidemiology, IVD biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Glutaric acidemia type I Indication Strategy Report 2026: GCDH, Trials and Deals
23 July 2026
2026 Glutaric acidemia type I strategy: epidemiology, GCDH biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Alkaptonuria Indication Strategy Report 2026: HGD, Trials and Deals
23 July 2026
2026 Alkaptonuria strategy: epidemiology, HGD biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Tyrosinemia type I Indication Strategy Report 2026: FAH, Trials and Deals
23 July 2026
2026 Tyrosinemia type I strategy: epidemiology, FAH biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Rhizomelic chondrodysplasia punctata Indication Strategy Report 2026: PEX7, Trials and Deals
23 July 2026
2026 Rhizomelic chondrodysplasia punctata strategy: epidemiology, PEX7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Refsum disease Indication Strategy Report 2026: PHYH, Trials and Deals
23 July 2026
2026 Refsum disease strategy: epidemiology, PHYH biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Zellweger spectrum disorder Indication Strategy Report 2026: PEX1, Trials and Deals
23 July 2026
2026 Zellweger spectrum disorder strategy: epidemiology, PEX1 biology, clinical competition, recent deals, unmet need and market attractiveness.